Norma O'Donovan

TL;DR: The optimum use of survivin antagonists in the treatment of cancer is likely to be in combination with conventional cancer therapies, including use of the antisense oligonucleotide LY2181308, the low molecular weight molecule inhibitor YM155 and survivin-directed autologous cytotoxic T lymphocytes.

TL;DR: Although the TNBC cells are less sensitive to EGFR inhibition than the HER-2-positive cell lines, gefitinib enhanced response to chemotherapy and combined with carboplatin and docetaxel warrants further investigation in TNBC.

TL;DR: Investigation of the role of receptor tyrosine kinase signaling and phosphoinositide 3-kinase (PI3K)/AKT pathway activation in conferring resistance to trastuzumab and lapatinib concluded that pharmacologic targeting of the PI3K/AKT pathways may provide benefit to HER2-positive breast cancer patients who are resistant totrastuzuab therapy.

TL;DR: Emerging data suggests that measurement of survivin can aid the early diagnosis of bladder cancer, determine prognosis in multiple cancer types and predict response to diverse anti-cancer therapies.

TL;DR: Key decisions to be made prior to starting resistant cell line development are discussed; the choice of parent cell line, dose of selecting agent, treatment interval, and optimizing the dose of drug for theparent cell line.